Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RPT193 in Adults With Moderate-to-severe T2-high Asthma
NCT05935332Phase 2Terminated
- Sponsor
- RAPT Therapeutics
- Start
- Jul 2023
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 4
01
Overview
A Phase 2 trial of zelnecirnon in asthma, sponsored by RAPT Therapeutics. Started Jul 2023; status: terminated.
02
Drugs
zelnecirnon
03
Conditions
asthma
Beyond the preview
Go deeper on NCT05935332.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05935332.